Psoriatic Arthritis

The FDA announces it did not meet the June 25 PDUFA action date on the sNDA for active psoriatic arthritis treatment, upadacitinib.

COSMOS phase 3b study data demonstrated the effectiveness of guselkumab in patients diagnosed with psoriatic arthritis.

Biologic therapy has proven very useful in treating an increasing number of dermatologic diseases and conditions. However, caution is warranted for patients with chronic infectious diseases.

Novel biologics are moving into off-label indications to expand the dermatologic armamentarium for a broad range of inflammatory skin diseases.

Voltaire-X study data shows that switching several times between Cyltezo and Humira results in similar pharmacokinetics, efficacy, immunogenicity, and safety in people with moderate to severe chronic plaque psoriasis.

Phase 3 trial of Otezla shows improved measures of disease severity in adults with mild to moderate plaque psoriasis regardless of their Body Surface Area affected by the disease.

AbbVie announces the submission of regulatory filings for risankizumab to the FDA and EMA seeking approval for the drug as a treatment for psoriatic arthritis.

Safety profiles remain consistent longer-term but cost and accessibility are major challenges for biologics aimed at treating psoriasis.

Ixekizumab demonstrated long-term efficacy in treating psoriasis and psoriatic arthritis across five years, according to data presented by Eli Lilly at the 29th annual European Academy of Dermatology and Venereology (EADV) Congress.

The U.S. FDA has approved to expand the indication for golimumab (SIMPONI ARIA, Janssen Pharmaceutical Companies of Johnson & Johnson) to include it was a treatment for active psoriatic arthritis (PsA) in pediatric patients 2 years and older.

Guselkumab becomes the first IL-23 inhibitor approved for treatment of psoriatic arthritis by the U.S. Food and Drug Administration (FDA) following positive phase 3 results from two trials investigating the safety and efficacy of the drug.

The U.S. Food and Drug Administration has approved Mylan and Fujifilm Kyowa Kirin Biologics’ adalimumab-fkjp as a biosimilar to AbbVie’s adalimumab for a variety of inflammatory disease including plaque psoriasis and psoriatic arthritis.

AbbVie announces they have filed applications with the U.S. FDA and EMA for the approval of the JAK inhibitor upadacitinib for the treatment of adult active psoriatic arthritis.

A recent study shows promising results for using ultrasound to examine hand tendon and joint inflammation in psoriatic arthritis patients.

This slideshow breaks down important considerations to keep in mind when evaluating psoriasis patient for psoriatic arthritis.

A recent study discovered that body mass index (BMI) and age of disease onset may play a part in the development of hypertension in psoriatic arthritis and psoriasis. Read what researchers found in this article.

Researchers employed the the Citizen Pscientist, an online patient portal developed by the National Psoriasis Foundation, to investigate chronic sleep dysfunction prevalence in psoriasis. Read what they discovered in this article. 

A recent study found that Psoriasis Epidemiology Screening Tool (PEST) may help dermatologists identify which patients need a rheumatology referral. 

According to a recent study, patients with psoriatic arthritis may be at a greater risk for adult hearing loss than individuals without psoriatic arthritis.

For psoriasis patients, the most common comorbidity they may experience is psoriatic arthritis. Knowing how to identify and treat it can be critical.

The prevalence of psoriatic arthritis in patients with psoriasis worldwide appears to be around 20 percent, shows a meta-analysis published in JAAD.

Many tools and strategies can help dermatologists overcome their discomfort in addressing psoriatic arthritis (PsA) in patients with psoriasis, physicians report.

In June, the European Commission approved tofacitinib citrate (Xeljanz/Pfizer) 5 mg twice daily in combination with methotrexate for adults with psoriatic arthritis. Learn about the parameters here.

In inflammatory arthritis, the molecular and genetic makeup of synovial tissues appears to hold clues that one day may guide clinical decision-making. Re: EULAR report.

A new methotrexate usage survey shows that most patients with arthritis do not discuss medication modification strategies with their doctors.